Bottom line
Is BIB a good fund? The bottom line
BIB is an actively managed technology sector ETF from ProShares.
Annual fees run 0.95% — about $95 a year on every $10,000 invested, more expensive than 67% of technology sector funds we track.
It returned +59.3% over one year, −1.0% a year over five years, +1.4% a year over ten (as of Dec 31, 2025, per its prospectus).
With $73.7 million in net assets and 267 holdings, its largest position is N/a (7.4%) and the top 10 make up 43% of the portfolio.
The closest lower-cost alternative we found is IBBQ (0.19%, 51% top-holdings overlap).
What stands out
- Broadly diversified (267 holdings)
What to watch
- 5-year return in the bottom quarter of its category
Updated Nov 19, 2026
What BIB invests in
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index (the Index).
The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. The Index includes companies listed on the Nasdaq Global Select Market or the Nasdaq Global Market (which include both U.S. and non-U.S. companies) that are included in the biotechnology or pharmaceuticals subsectors, according to the Industry Classification Benchmark. The biotechnology and pharmaceutical subsectors include companies engaged in research into and development of biological substances for the purposes of drug discovery and diagnostic development and manufacturers of prescription or over-the-counter drugs. Companies are selected based on market capitalization and liquidity. Selected companies are then…
From the fund's prospectus (filed Sep 25, 2026).
BIB performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| BIB | +59.3% | −1.0% | +1.4% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What BIB costs
On a $10,000 investment, BIB's 0.95% expense ratio costs about $95 a year. The prospectus estimates $1,401 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
BIB top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | N/a | 7.35% |
| 2 | ProShares GENIUS Money Market ETF | 6.80% |
| 3 | Gilead Sciences, Inc. | 4.66% |
| 4 | Vertex Pharmaceuticals, Inc. | 4.65% |
| 5 | Amgen, Inc. | 4.48% |
| 6 | N/a | 3.94% |
| 7 | N/a | 3.26% |
| 8 | Regeneron Pharmaceuticals, Inc. | 3.21% |
| 9 | N/a | 2.62% |
| 10 | Alnylam Pharmaceuticals, Inc. | 2.01% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 43% of the fund. See all top 25 holdings and asset mix →